Potential Medicare Part D Savings on Ophthalmic Generic Drugs

JAMA Ophthalmol. 2024 Jul 1;142(7):678-680. doi: 10.1001/jamaophthalmol.2024.1717.
No abstract available

Plain language summary

This economic evaluation assesses potential Medicare Part D savings on ophthalmic generic drugs if discount coupon prices are used.

MeSH terms

  • Cost Savings
  • Drug Costs*
  • Drugs, Generic* / economics
  • Humans
  • Medicare Part D* / economics
  • Ophthalmic Solutions
  • United States

Substances

  • Drugs, Generic
  • Ophthalmic Solutions